Summary This double-blind multicentre study has been carried out in order to confirm the improvement of ondansetron's antiemetic efficacy when combined with a corticosteroid and to determine whether this increased efficacy is maintained over three chemotherapy courses 
In many cancer types, cisplatin is one of the most effective cytotoxic drugs currently available, but it is also one of the most emetogenic (Hellenbrecht & Saller, 1986) .
Ondansetron is an antagonist of the 5-HT3 serotonin receptors; its antiemetic efficacy is superior to that of highdose metoclopramide in the prevention of cisplatin-induced nausea and vomiting (De Mulder et al., 1990; Hainsworth et al., 1991; Marty & d'Allens, 1990) .
In a recent study, it was demonstrated that a single 8 mg ondansetron i.v. injection is as effective as a single 32 mg i.v. injection in the prevention of acute emetic episodes in patients receiving their first course of chemotherapy (Seynaeve et al., 1992) . Similarly, it was demonstrated in another recent study that the antiemetic efficacy of ondansetron administered at a dose of 8 mg every 12 h in the prevention of the prolonged emesis seen after non-cisplatin chemotherapy is similar to the efficacy of a dose of 8 mg administered every 8 h (Dicato et al., 1992) . Corticosteroids in combination with metoclopramide (Kris et al., 1985) or ondansetron (Roila et al., 1991) can increase the antiemetic efficacy of these compounds. This synergetic activity with ondansetron was studied closely in the control of acute emesis during a first course of chemotherapy (Roila et al., 1991; Smyth et al., 1991) .
The aim of this study was to confirm the improvement in the antiemetic activity of ondansetron in combination with a corticosteroid on the day of the cisplatin administration, and on subsequent days; moreover, the combination was studied over a further two successive courses. day of the study, with a maximum duration of infusion up to 4 h were admitted to the study. The scheduled treatment was to include at least three chemotherapy courses, each with a time interval of 2-5 weeks. Cisplatin was administered at the dosage and mode as specified for the first course.
Patients must have had no vomiting or retching requiring an antiemetic treatment during the 24 h prior to the start of the study. Moreover, patients who received other active antiemetic drugs because of episodes of vomiting which were unrelated to chemotherapy could not be included in this study.
The protocol was approved by the Ethics Committee of St Louis Hospital, Paris. This study was conducted in accordance with good clinical practice and the Declaration of Helsinki, each patient having given written informed consent.
Methodology and calculation of the required number of subjects This was a multicentre, randomised, parallel-group, doubleblind study.
The required number of patients was based on a complete response (no emetic episode) rate being experienced by 55% of patients on the first day of the first chemotherapy course with ondansetron alone, and in 80% of patients when combined with methylprednisolone.
Therefore, the minimum number of evaluable patients required was 46 per group, with a risk of a = 5% and a power of 80% (one-sided test), i.e. a total of 92 patients.
Antiemetic treatments studied The patients were randomised to one of the two following groups: treatment was established by the investigator, and in case of E a serious adverse event a drug surveillance enquiry was made to assess the degree of causality with the study drug.
Statistical analysis +
All the patients were included in the efficacy analysis if they > had complied with the protocol during the first 24 h of the study. Treatments were compared over the first 24 h after the start of chemotherapy, on the worst day between day 2 and 0 * day 6 and over the whole chemotherapy course. These com-., _ parisons were made on the four-class repartition over the E three successive chemotherapy courses. Control of delayed emetic episodes (Table IV) The control of delayed emetic episodes occurring on the worst day between day 2 and day 6 shows a trend for the combination to be superior, resulting in an improved continuous antiemetic efficacy over the three courses of chemotherapy. The difference was statistically significant during the second and third courses of chemotherapy.
Global control of emetic episodes (Table V) The analysis of the global antiemetic response for each chemotherapy course shows a better maintained anti-emetic efficacy with the combination over the three courses.
Safety
The adverse events reported during the three previous courses are presented in resolved despite the continuation of the antiemetic treatment. No other serious adverse event linked with the treatment was reported during the study.
Discussion
Both study treatment groups were well balanced for the main prognostic factors (Clavel, 1991) of chemotherapy-induced emesis (age, alcohol consumption and cisplatin dose). Females, in whom the emetic risk is higher, were in a higher proportion in the ondansetron/methylprednisolone group, although the difference was not statistically significant. However, in order to take into account this difference between the two groups for this major prognostic factor, the overall statistical tests were adjusted for sex.
The results of this study confirm the usual rates of antiemetic response seen with ondansetron when administered alone as a single 8 mg i.v. injection in patients following high-dose cisplatin-containing chemotherapy : Seynaeve et al., 1992 : this success rate, 70% during the 24 h following chemotherapy, was also seen in the two following courses.
As already reported by many authors (Roila et al., 1991; Smyth et al., 1991) , the antiemetic efficacy of ondansetron in combination with corticosteroids is enhanced in acute emesis in patients following moderately emetogenic chemotherapies, with 90% of patients being showing complete or major response on the first day of chemotherapy. The results noted for nausea show the superiority of the combination.
Oral administration of an 8 mg tablet twice daily led to complete or major control in two out of three patients on the worst day; higher success rates were obtained in another study, with less emetogenic chemotherapy (Dicato et al., 1991) than those of the present study, which involved high doses of cisplatin (mean dose 90 mg m-2). The methylprednisolone dose administered in delayed emesis is roughly equivalent to the dexamethasone dose used in another study (Kris et al., 1989) which showed the advantage of using corticosteroids in the delayed phase.
The findings with ondansetron in combination with methylprednisolone in delayed emesis confirm the efficacy of such a combination, even if we have to take into account the probable impact on the delayed phase of a superior efficacy in the first 24 h (Smyth et al., 1991) . Among the patients evaluable at each course, the efficacy is maintained over the subsequent chemotherapeutic courses, with 67% of patients experiencing complete response on the worst day of the third course.
Ondansetron in combination with methylprednisolone permits a better maintained antiemetic activity over the chemotherapy courses, with 74% of patients reporting complete or major response during the third mildly emetogenic chemotherapeutic course (acute and delayed emesis). These results confirm two previous studies one covering three cisplatin-containing chemotherapy courses (Italian Group for Anti-emetic Research, 1993) and the other one covering six moderately emetogenic chemotherapeutic courses (Soukop et al., 1992) . However in these two studies corticosteroids were given only on the first day of each course. The present study confirms the major antiemetic efficacy of ondansetron and corticosteroids in combination already mentioned by various authors (Roila et al., 1991; Smith et al., 1991; Soukop et al., 1992) and confirms its activity over three identical chemotherapy courses. Moreover, this combination has shown its superiority over some of the reference antiemetic regimens: metoclopramide, dexamethasone and diphenhydramine (Italian Group for Anti-emetic Research, 1992) .
Overall, both treatments were well tolerated, with a trend towards a lower rate of adverse events in the OND/MPD group, in particular a decreased frequency of headache; this trend has already been noted in other studies combining ondansetron with corticosteroids Roila et al., 1991; Smith et al., 1991) .
Our study clearly confirms the increased antiemetic efficacy of ondansetron plus methylprednisolone in combination in both acute and delayed cisplatin-induced emesis, and shows a better maintained antiemetic efficacy over three chemotherapy courses without undue safety problems.
